Clinical Trials Logo

Clinical Trial Summary

Many cardiac patients requiring device (defibrillator or pacemaker) related surgery are on chronic oral anticoagulation therapy (usually coumadin). The risk of blood clot formation related to stopping oral anti-coagulant therapy is currently managed by using bridging heparin therapy in patients with moderate to high risk of blood clot formation. There is a substantial risk of bleeding in the pocket where the device is situated (pocket hematoma)related to bridging therapy. The purpose of this study is to compare the current standard of care of bridging with heparin to an experimental strategy of continuing coumadin therapy in higher risk patients undergoing device surgery, with the hypothesis being that the continued oral anti-coagulation group will have a lower pocket hematoma rate as compared to the bridging with heparin group.


Clinical Trial Description

Eligible patients will be equally randomized (1:1) to the Conventional/control arm (bridging anti-coagulation)or to the Experimental arm (continued coumadin). In the Conventional arm there are 2 options. Patients with greater than 5 days pre-implant will discontinue oral anti-coagulant (coumadin) 5 days before the procedure,and start full therapeutic doses of subcutaneous low molecular weight heparin (LMWH)3 days before the procedure. Patients with less than 5 days to implant can be given Vitamin K at the investigator's discretion and start full therapeutic doses of either subcutaneous LMWH or IV unfractionated Heparin (choice is at investigator discretion) when the INR is below the therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6. Oral anti-coagulant (coumadin) will resume on the evening of the procedure. Full dose LMWH injections or full dose IV heparin will be started 24 hours after surgery.

In the Experimental arm patients will continue on their oral anti-coagulant (coumadin). The INR on the day of surgery will be < 3.0.

ASA will be continued in all patients. Plavix will be continued in patients with drug-eluting stents.

Patients will be monitored for the development of any hematoma or bleeding event during admission. There will be a unblinded team responsible for device implant and follow-up and a blinded team responsible to monitor any bleeding events or hematoma and determine if it meets the primary endpoint criteria for the study. The blinded team will have no knowledge of the treatment arm and will be involved only if the patient develops a hematoma or bleeding event. All hematomas and bleeding events will be followed until resolution. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00800137
Study type Interventional
Source Ottawa Heart Institute Research Corporation
Contact
Status Terminated
Phase Phase 4
Start date December 2008
Completion date March 2013

See also
  Status Clinical Trial Phase
Completed NCT02821325 - Intra-articular Volumetric Assessment After Total Knee Arthroplasty N/A
Not yet recruiting NCT04496180 - Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy N/A
Completed NCT03280043 - Risk of Hematoma After Ketorolac Use in Reduction Mammoplasty. N/A
Completed NCT00409058 - Teen Online Problem Solving (TOPS) - An Online Intervention Following TBI N/A
Completed NCT04046952 - Comparing TR Band to Statseal in Conjunction With TR Band II N/A
Completed NCT05729334 - Clinical Investigation EUCLIDES-01 for the Calculation of the Area of Skin Lesions N/A
Recruiting NCT05637645 - Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section N/A
Recruiting NCT02982733 - Ankaferd Blood Stopper for Hemostasis After Transradial Coronary Angiography N/A
Not yet recruiting NCT02967627 - VAC Dressings for Colorectal Resections N/A
Completed NCT01026649 - The 2-stage Approach for Reducing Posterior Wall Puncture During the Internal Jugular Vein Catheterization N/A
Active, not recruiting NCT05210868 - A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) Phase 1/Phase 2
Withdrawn NCT04359017 - Systemic Absorption of Lidocaine After Hematoma Block Phase 4
Recruiting NCT05292326 - Safety and Efficiency of the PacePress to Prevent Hemorrhagic Complications in Patients Undergoing CIED Implantation. N/A
Completed NCT03067909 - Antithrombotic Therapy in Patients Undergoing CIED Surgery - HEMATOMA NO MORE Registry
Completed NCT01112735 - Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty Phase 2
Completed NCT05577832 - Testing Different Methods of Intramuscular Injection N/A
Terminated NCT04818580 - Progressive Tension Sutures in Gender Affirming Mastectomy N/A
Not yet recruiting NCT05247073 - Mostafa Maged Four-stitch Technique in Closure the Episiotomy During Vaginal Delivery N/A
Completed NCT01498315 - The Incidence of Pelvic Hematoma Following Hysterectomy N/A
Recruiting NCT04783922 - An Update on Intracerebral Hemorrhage